期刊
TRANSPLANT INFECTIOUS DISEASE
卷 11, 期 2, 页码 167-170出版社
WILEY
DOI: 10.1111/j.1399-3062.2008.00345.x
关键词
Pneumocystis jirovecii; pneumonia; rituximab; antibody-mediated rejection; renal transplant
D. Kumar, S. Gourishankar, T. Mueller, S. Cockfield, J. Weinkauf, D. Vethanayagam, A. Humar. Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient.Transpl Infect Dis 2009: 11: 167-170. All rights reserved We report the case of a 54-year-old woman who underwent living-related renal transplantation for end-stage renal disease from IgA nephropathy. She was subsequently diagnosed with antibody-mediated rejection (AMR) and received rituximab, a potent B-cell suppressive agent. After therapy with rituximab, she developed Pneumocystis jirovecii pneumonia (PJP) requiring hospitalization. We discuss the increasing literature for the use of rituximab for AMR and the need for PJP prophylaxis in this setting.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据